Fluvoxamine may prevent serious illness in COVID-19 patients

(Washington University School of Medicine) Researchers at Washington University School of Medicine in St. Louis have completed a clinical trial suggesting that the antidepressant drug fluvoxamine may help prevent deterioration in COVID-19 patients, making hospitalization less likely.